Two new real-world studies evaluated the use of intravenous immune globulin (IVIG) therapy plus glucocortioids for treatment of post–COVID-19 multisystem inflammatory syndrome in children (MIS-C), one finding a lower risk of new or persistent cardiovascular dysfunction with the combination treatment and the other showing no lessening in disease severity or time to recovery.The studies and a related editorial were published last week in the New England Journal of Medicine.Drug combo may help protect the heartIn the first study, the Overcoming COVID-19 Investigators, led by Boston Children's Hospital researchers, analyzed surveillance data on 518 MIS-C patients 20 years and younger receiving at least one immune response-enhancing drug at 58